Lonza Group stock holds near CHF 450 after 2024 earnings reset

Shares and valuation

Lonza Group (CH0013841017) stock traded at CHF 450.00 as of August 12, 2026, with market capitalization at CHF 38.0 billion, giving investors a current reference point after the earlier earnings reset that followed the 2024 results the ad hoc news report.

The same report puts the stock near the middle of its recent range, below the earlier CHF 520 peak, and frames the valuation gap in a concrete way: the equity value has dropped by about CHF 6 billion from the higher level implied at the peak.

What the last report showed

For the most recent reported full year in the search results, Lonza generated CHF 6.0 billion in group sales in 2024, down from CHF 6.7 billion in 2023, while core EBITDA slipped to CHF 1.6 billion from CHF 1.9 billion.

Net profit from continuing operations was CHF 0.9 billion in 2024 versus CHF 1.1 billion in 2023, a decline of CHF 0.2 billion that shows how capacity utilization and investment spending weighed on earnings power.

Why the comparison matters

The key investor takeaway is that the market value at CHF 38.0 billion is still being judged against a 2024 earnings base that is materially smaller than the prior year, so the stock remains sensitive to any sign of margin recovery, volume normalization or a better utilization trend.

For peer context, Lonza's Swiss listing finished the last completed session at CHF 573.80 on August 13, 2026 in one market overview, which places the company well above the CHF 450 reference point in the separate stock snapshot and highlights how venue and snapshot timing can change the picture.

Biologics manufacturing

Lonza's contract development and manufacturing work is still tied to large-scale biologics and specialty ingredients projects, so the business continues to depend on plant utilization, customer programs and the pace of manufacturing ramp-ups.

The 2024 figures show why that matters: CHF 6.0 billion in sales, CHF 1.6 billion in core EBITDA and CHF 0.9 billion in continuing profit leave little room for a weak utilization backdrop.

Stock view

Lonza stock remains a valuation and execution story, with CHF 450.00 as the latest quoted reference and CHF 38.0 billion as the market value anchor in the August 12, 2026 snapshot.

Company

Company: Lonza Group AG
ISIN: CH0013841017
Ticker: LONN
Exchange: SIX Swiss Exchange
Price (as of August 12, 2026, 4:00 p.m. CET): CHF 450.00
Market cap: CHF 38.0 billion (as of August 12, 2026)
Sector / Industry: Health Care / Pharmaceuticals
Index membership: Swiss Market Index

More on Lonza Group stock

Lonza Group AG is a Swiss CDMO and specialty ingredients company. Its biologics and manufacturing platform is the part of the business that most directly links utilization, margins and order flow.

Lonza Group shares

Lonza Group shares are quoted on the SIX Swiss Exchange, and the latest stock snapshot in this call shows CHF 450.00 on August 12, 2026.